AstraZeneca Reports Results of AZD1222 in Interim Analysis of P-lll Program for COVID-19
Shots: The results of an interim of P-III program demonstrated that AZD1222 is safe & effective at preventing symptomatic COVID-19 and hospitalization. The interim analysis for efficacy was based on ~11,636 participants accruing 131 symptomatic infections from the P-III UK and Brazil trials The 1EPs based on the pooling of two dosing regimens showed vaccine […]